VYGR — Voyager Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1640266 ·
Last close
$1.52
Market Cap
$94.59M
52W High
$5.48
52W Low
$1.50
ADV30
1,004,482
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 4,014,000 | — | -26,422,000 | -24,694,000 | 177,053,000 | 48,408,000 | 41,942,000 |
| Jun 2026 | 3,165,000 | — | -26,392,000 | -24,473,000 | 197,753,000 | 35,769,000 | 43,376,000 |
| Mar 2026 | 2,593,000 | — | -30,270,000 | -27,937,000 | 219,325,000 | 43,314,000 | 45,656,000 |
| Dec 2025 | 15,336,000 | — | -29,932,000 | -27,426,000 | 252,281,000 | 65,300,000 | 56,200,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-120,572,000
Investing CF
$105,804,000
Financing CF
$6,459,000
CapEx
$-1,952,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.81
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-498,315,000
Inventory
—
Receivables
$3,154,000
ST Investments
$80,569,000
EBIT TTM
$-117,188,000
Pretax Income TTM
$-107,602,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$25,108,000
EBITDA
$-105,791,000
Free Cash Flow
$-64,756,500
Enterprise Value
$39,758,424
Total Cash
$106,806,000
Total Debt
$30,507,000
Shares Out
62,229,182
Trailing EPS
$-1.74
Book Value
$2.17
ROE
-58.9%
ROA
-29.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 40,374,000 | -131,844,000 | -119,721,000 | 252,281,000 | 56,200,000 | 196,081,000 | -132,467,000 |
| Dec 2024 | 80,001,000 | -83,287,000 | -65,002,000 | 393,050,000 | 93,290,000 | 299,760,000 | -15,310,000 |
| Dec 2023 | 250,008,000 | 122,014,000 | 132,330,000 | 351,281,000 | 114,961,000 | 236,320,000 | 77,919,000 |
| Dec 2022 | 40,907,000 | -50,837,000 | -46,408,000 | 159,356,000 | 100,336,000 | 59,020,000 | -12,509,000 |
TTM Snapshot
Revenues TTM
$34,459,000
NetIncome TTM
$-107,728,000
OpCashFlow TTM
—
Assets (Latest)
$197,753,000
Forward EPS
$-1.28
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $1.67 · call volume: 169 · put volume: 341
Expected Move to 2027-04-16:
±$1.47
(88.02%) —
implied range
$0.20 –
$3.14
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARMP | Armata Pharmaceuticals, Inc. | $98.93M | $2.66 | — |
| ZURA | Zura Bio Ltd | $99.70M | $1.03 | — |
| OTLK | Outlook Therapeutics, Inc. | $87.79M | $0.36 | — |
| VXRT | Vaxart, Inc. | $86.51M | $0.35 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $82.75M | $1.44 | — |
News headlines (Yahoo Finance, 1h cache)
Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer’s Gene Therapy Dosing
2026-11-16 06:12 · Yahoo
Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 21:45 · Yahoo
Voyager Therapeutics: Q3 Earnings Snapshot
2026-11-05 21:34 · Yahoo
Voyager Reports Third Quarter 2026 Financial and Operating Results
2026-11-05 21:01 · Yahoo
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
2026-10-27 12:01 · Yahoo
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
2026-10-21 12:01 · Yahoo
Voyager to Present at Upcoming Investor Conferences
2026-09-01 12:00 · Yahoo
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
2026-08-06 23:10 · Yahoo
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
2026-07-13 12:01 · Yahoo
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money
2026-07-02 13:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.